ArticleCurrent microbiology2026
Rising Burden of ESBL-Producing Escherichia coli and Klebsiella pneumoniae in Burkina Faso: A Five-Year Retrospective Analysis.
Article in Current microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extended-spectrum β-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae are major contributors to antimicrobial resistance worldwide. Data from Burkina Faso remain limited, despite growing concerns about multidrug resistance in urinary pathogens. We conducted a retrospective cross-sectional study using microbiological records from three medical laboratories in Ouagadougou between January 2018 and December 2022. All urine culture isolates of E. coli and K. pneumoniae were included. Patient demographics, hospitalization status, and antimicrobial susceptibility profiles were extracted. ESBL production was confirmed phenotypically using the double disk synergy test. Statistical analyses were performed to compare prevalence and resistance patterns across species and patient groups. A total of 4,234 isolates were analyzed, comprising 3,084 E. coli (72.8%) and 1,150 K. pneumoniae (27.2%). ESBL prevalence rose from 3.8% in 2018 to 24.7% in 2022, with E. coli consistently showing higher rates in later years. Sociodemographic analysis revealed significantly higher ESBL prevalence among patients aged ≥ 60 years compared with younger age groups (18.9%), hospitalized patients compared with outpatients (16.9% vs. 14.1%; p = 0.02), and male patients compared with females (17.5% vs. 14.5%; p = 0.015). ESBL producers demonstrated markedly greater resistance to fluoroquinolones, and aminoglycosides (p < 0.001), while carbapenems remained largely effective. ESBL prevalence among urinary isolates in Ouagadougou has increased substantially, with E. coli emerging as the predominant producer. The association with older age, inpatient status, and male gender highlights key risk groups. These findings underscore the urgent need for strengthened antimicrobial stewardship, infection control, and expanded surveillance across Burkina Faso.
Indexed as
Identifiers
42177386What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.